SMi is delighted to welcome: Carlos Camozzi, Vice President & Chief Medical Officer at uniQure, to their inaugural Orphan Drugs & Rare Diseases conference taking place next week on 8th & 9th October 2012 in London. Dr. Camozzi will be joining leading leaders in gene therapy and rare diseases.

(PRWEB UK) 1 October 2012

Jrn Aldag, chief executive of UniQure, says that the announcement from the EMA is an overdue signal to the gene-therapy community that things are changing. It unlocks the potential, he says, quoted in Nature. You will see more investment coming.*

Perhaps as important is UniQures pioneering annuity approach to reimbursement, staggering payments over the five years for which treatment has been proved to work. As highlighted by the Financial Times, such financial innovation may prove as important as the scientific breakthroughs that led to the treatment in the first place**.

Other keynote speakers presenting at this outstanding event include:

Visit http://www.smi-online.co.uk/goto/orphandrugs-event38.asp to secure your place now!

Alternatively, contact Alternatively Contact Fateja Begum on telephone +44 (0) 20 7827 6184 or email on fbegum@smi-online.co.uk

** Healthcare: Uncommon complaints. Financial Times, July 25th, 2012, p.9.

About SMi Group

The SMi Group is a world leader in business to business information. With nearly two decades in the business, thousands of senior executives from blue chip companies have already benefitted from SMis highly targeted conferences, workshops and publications. For more information visit:

View post:
Orphan Drugs & Rare Diseases conference

Comments are closed.